Skip to main content
Quest Diagnostics

Minimal residual disease testing offers major benefits in oncology care

Cancer treatment for solid tumors has advanced rapidly in recent years, giving many patients significantly better prognoses compared to just a decade ago. But oncologists know that at the end of even the most advanced treatment regimen, patients may be left with small clusters of cells that remain tumorigenic. Detecting the presence of such cells is the goal of minimal residual disease (MRD) testing.

Complete the form to access an in-depth webinar discussion between 2 experts on the advancements in personalized diagnostics and cancer care.

Access the webinar: Improving oncology outcomes with MRD testing

839

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.